CY1121734T1 - ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ - Google Patents
ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑInfo
- Publication number
- CY1121734T1 CY1121734T1 CY20191100676T CY191100676T CY1121734T1 CY 1121734 T1 CY1121734 T1 CY 1121734T1 CY 20191100676 T CY20191100676 T CY 20191100676T CY 191100676 T CY191100676 T CY 191100676T CY 1121734 T1 CY1121734 T1 CY 1121734T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- borrelia infection
- mutant ospa
- polypeptide
- antibody
- Prior art date
Links
- 108700006640 OspA Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 206010061591 Borrelia infection Diseases 0.000 abstract 3
- 101710105714 Outer surface protein A Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 210000004900 c-terminal fragment Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση αφορά συνθέσεις και μεθόδους για την προληπτική και θεραπευτική αγωγή μόλυνσης Borrelia. Συγκεκριμένα, η παρούσα εφεύρεση αφορά ένα πολυπεπτίδιο που περιλαμβάνει ένα υβριδικό C-τελικό θραύσμα μίας εξωτερικής επιφανειακής protein A (OspA), ένα νουκλεϊκό οξύ που κωδικοποιεί αυτήν, ένα αντίσωμα που δεσμεύει ειδικά αυτήν, μία φαρμακευτική σύνθεση (συγκεκριμένα για χρήση ως ένα φάρμακο ή σε μία μέθοδο θεραπευτικής ή προληπτικής αγωγής μίας μόλυνσης Borrelia) που περιλαμβάνει το πολυπεπτίδιο και/ή το νουκλεϊκό οξύ, και/ή το αντίσωμα, μία μέθοδο θεραπευτικής ή προληπτικής αγωγής μίας μόλυνσης Borrelia και μία μέθοδο ανοσοποίησης ενός υποκειμένου.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14150682 | 2014-01-09 | ||
| EP15703228.5A EP3092246B1 (en) | 2014-01-09 | 2015-01-09 | Mutant fragments of ospa and methods and uses relating thereto |
| PCT/EP2015/050365 WO2015104396A1 (en) | 2014-01-09 | 2015-01-09 | Mutant fragments of ospa and methods and uses relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121734T1 true CY1121734T1 (el) | 2020-07-31 |
Family
ID=49917594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100676T CY1121734T1 (el) | 2014-01-09 | 2019-06-27 | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9975927B2 (el) |
| EP (2) | EP3564257A1 (el) |
| JP (1) | JP6505110B2 (el) |
| KR (1) | KR102460165B1 (el) |
| CN (1) | CN105980398B (el) |
| AU (1) | AU2015205520B2 (el) |
| BR (2) | BR122023024315A2 (el) |
| CA (1) | CA2931110A1 (el) |
| CY (1) | CY1121734T1 (el) |
| DK (1) | DK3092246T3 (el) |
| EA (1) | EA034554B1 (el) |
| ES (1) | ES2740985T3 (el) |
| HR (1) | HRP20191086T1 (el) |
| HU (1) | HUE043779T2 (el) |
| LT (1) | LT3092246T (el) |
| MX (1) | MX369195B (el) |
| NZ (1) | NZ721015A (el) |
| PL (1) | PL3092246T3 (el) |
| PT (1) | PT3092246T (el) |
| RS (1) | RS59075B1 (el) |
| SI (1) | SI3092246T1 (el) |
| SM (1) | SMT201900383T1 (el) |
| TR (1) | TR201910117T4 (el) |
| WO (1) | WO2015104396A1 (el) |
| ZA (1) | ZA201602690B (el) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| SMT201900383T1 (it) | 2014-01-09 | 2019-09-09 | Valneva Austria Gmbh | Frammenti mutanti di ospa e metodi e utilizzi correlati ad essi |
| CA3059817A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
| CN110483624B (zh) * | 2019-08-22 | 2021-02-09 | 中国疾病预防控制中心传染病预防控制所 | 伽氏疏螺旋体OspA蛋白C端肽段及其应用 |
| EP4146253A1 (en) * | 2020-04-09 | 2023-03-15 | Valneva Austria GmbH | Improvements in vaccine formulations for medical use |
| EP4132950A1 (en) | 2020-04-09 | 2023-02-15 | Valneva Austria GmbH | Compositions comprising three ospa fusion proteins for medical use |
| MX2023007135A (es) | 2020-12-17 | 2023-08-25 | Idexx Lab Inc | Detección y tratamiento de la fiebre de las montañas rocosas. |
| WO2023212520A1 (en) | 2022-04-25 | 2023-11-02 | Pfizer Inc. | Compositions and methods for eliciting an immune response protective against lyme disease |
| WO2024050512A2 (en) * | 2022-09-02 | 2024-03-07 | The Medical College Of Wisconsin, Inc. | Use of immunogenic t cell epitopes for lyme disease vaccination and diagnosis |
| WO2025015042A1 (en) | 2023-07-10 | 2025-01-16 | Dynavax Technologies Corporation | Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen |
| WO2025015077A1 (en) | 2023-07-10 | 2025-01-16 | Dynavax Technologies Corporation | Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| US6248562B1 (en) * | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| ATE381575T1 (de) | 2000-08-18 | 2008-01-15 | Univ New York State Res Found | Veränderte borrelia burgdorferi ospa |
| UA89481C2 (uk) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| EP2059526A2 (en) * | 2006-09-15 | 2009-05-20 | Intercell AG | Borrelia antigens |
| PL2484375T3 (pl) | 2006-09-26 | 2018-09-28 | Infectious Disease Research Institute | Kompozycja szczepionki zawierająca syntetyczny adiuwant |
| JP6030052B2 (ja) | 2010-05-14 | 2016-11-24 | バクスアルタ インコーポレイテッド | Ｏｓｐａキメラおよびそのワクチンでの使用法 |
| TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
| TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
| US8986704B2 (en) * | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| SMT201900383T1 (it) | 2014-01-09 | 2019-09-09 | Valneva Austria Gmbh | Frammenti mutanti di ospa e metodi e utilizzi correlati ad essi |
| CZ2014320A3 (cs) | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| CA3059817A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
-
2015
- 2015-01-09 SM SM20190383T patent/SMT201900383T1/it unknown
- 2015-01-09 US US15/110,151 patent/US9975927B2/en active Active
- 2015-01-09 PL PL15703228T patent/PL3092246T3/pl unknown
- 2015-01-09 RS RS20190970A patent/RS59075B1/sr unknown
- 2015-01-09 BR BR122023024315-3A patent/BR122023024315A2/pt not_active Application Discontinuation
- 2015-01-09 DK DK15703228.5T patent/DK3092246T3/da active
- 2015-01-09 BR BR112016015678A patent/BR112016015678B1/pt active IP Right Grant
- 2015-01-09 MX MX2016008989A patent/MX369195B/es active IP Right Grant
- 2015-01-09 CA CA2931110A patent/CA2931110A1/en active Pending
- 2015-01-09 EP EP19177679.8A patent/EP3564257A1/en active Pending
- 2015-01-09 LT LTEP15703228.5T patent/LT3092246T/lt unknown
- 2015-01-09 SI SI201530777T patent/SI3092246T1/sl unknown
- 2015-01-09 HU HUE15703228A patent/HUE043779T2/hu unknown
- 2015-01-09 PT PT15703228T patent/PT3092246T/pt unknown
- 2015-01-09 TR TR2019/10117T patent/TR201910117T4/tr unknown
- 2015-01-09 ES ES15703228T patent/ES2740985T3/es active Active
- 2015-01-09 CN CN201580003319.2A patent/CN105980398B/zh active Active
- 2015-01-09 KR KR1020167015981A patent/KR102460165B1/ko active Active
- 2015-01-09 EA EA201691095A patent/EA034554B1/ru unknown
- 2015-01-09 NZ NZ721015A patent/NZ721015A/en unknown
- 2015-01-09 EP EP15703228.5A patent/EP3092246B1/en active Active
- 2015-01-09 WO PCT/EP2015/050365 patent/WO2015104396A1/en active Application Filing
- 2015-01-09 JP JP2016541706A patent/JP6505110B2/ja active Active
- 2015-01-09 AU AU2015205520A patent/AU2015205520B2/en active Active
-
2016
- 2016-04-19 ZA ZA2016/02690A patent/ZA201602690B/en unknown
-
2018
- 2018-04-04 US US15/944,835 patent/US10766931B2/en active Active
-
2019
- 2019-06-17 HR HRP20191086 patent/HRP20191086T1/hr unknown
- 2019-06-27 CY CY20191100676T patent/CY1121734T1/el unknown
-
2020
- 2020-08-11 US US16/990,023 patent/US11572392B2/en active Active
-
2023
- 2023-01-06 US US18/150,971 patent/US20230322869A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| CY1123211T1 (el) | Meθοδoi γia th θepaπeytikh antimetωπισh ή thn προληψη thς hmikpaniaς | |
| CY1123697T1 (el) | Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη | |
| MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| EA201792501A1 (ru) | Вакцины для лечения и профилактики рака | |
| JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| NZ736285A (en) | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia | |
| EA202090275A2 (ru) | Антитела против с5 с улучшенными фармакокинетическими характеристиками | |
| MX361728B (es) | Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado. | |
| UA117045C2 (uk) | Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
| MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| CY1121805T1 (el) | Νουκλεϊνικο οξυ που περιλαμβανει ή κωδικοποιει στελεχος-βροχο ιστονης και πολυ(α) αλληλουχια ή σημα πολυαδενυλιωσης για αυξηση της εκφρασης ενος κωδικοποιημενου αντιγονου ογκου | |
| MX2020003806A (es) | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. |